ClinicalTrials.gg
RecruitingNCT07693283Updated Jul 9, 2026

Expression of Target in Endometriotic Lesions

An observational study in Endometriosis, sponsored by Beijing Tsinghua Chang Gung Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Beijing Tsinghua Chang Gung Hospital · Observational

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
40
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Endometriosis with a site in China — 16 open to participants now, 17 under way, 2 of them phase 3. Endometriosis · China.

Planned enrollment
17th of 19
40 · median 402
Started
2026
with 5 others
Observational
19 of 47
9 open now
Primary completion
2026-09
later than 5 of 16 live
Registered
41st of 47
by date
Lead sponsor
1 of 47
Beijing Tsinghua Chang Gung Hospital

Among the 47 studies in Endometriosis with a site in China, this one is the 17th largest by planned enrollment of the 19 observational ones that give a count, is one of 6 that started in 2026, is one of 19 observational ones, reaches primary completion later than 5 of the 16 other live ones, and was the 41st registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

16 of the 47 studies in Endometriosis with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Endometriosis with a site in China, or all of them as a file.
02

Study summary

Endometriosis is a common gynecological disorder associated with chronic pelvic pain and infertility, which affects women of reproductive age worldwide. This study aims to investigate the expression patterns of specific molecules in tissue specimens obtained from patients with endometriosis. The investigators will compare the expression levels of these molecules between endometriotic lesions and normal tissue. The primary objective of this study is to elucidate the potential roles of these molecules in the pathogenesis of endometriosis.

03

Conditions studied

  • Endometriosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female reproductive-aged patients with histopathologically confirmed endometriosis . Patients with malignant gynecological diseases are excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed endometriosis via laparoscopy and histopathological examination
  • Complete clinical and pathological data available

Exclusion criteria

Exclusion Criteria:

  • History of any malignant tumor
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • patients with endometriosis

    Other: Retrospective molecular expression analysis in endometriosis tissue specimens

Interventions

  • OtherRetrospective molecular expression analysis in endometriosis tissue specimens

    This study involves no prospective interventional measures for participants.

06

What researchers measure

Primary outcomes

  1. Expression levels of molecular in endometriotic lesions and adjacent normal tissue

    Standardized pathological histology assessment method

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Jul 9, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Feb 12, 2027
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07693283
Responsible party
Lei Zhang (Principal investigator, Beijing Tsinghua Chang Gung Hospital) — Principal investigator
First posted
Jul 9, 2026
Start date
Apr 13, 2026
Primary completion
Sep 30, 2026 (estimated)
Completion
Feb 12, 2027 (estimated)
Last update
Jul 9, 2026

Study contacts

Lei Zhang
Contact
461458953@qq.com
+86 186 0113 0459
Lei Zhang
principal investigator · Beijing Tsinghua Changgeng Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion